Canadian Drug Companies

[Onthego]

AEMD NR 04/05/2006 at .78

Aethlon Medical CEO Named to Biodefense Panel at the 2006 Homeland and Global Security Summit


2006-04-05 09:00 ET - News Release

SAN DIEGO -- (Business Wire) -- April 5, 2006
Company Website: http://www.aethlonmedical.com

Aethlon Medical, Inc. (OTCBB:AEMD), a pioneer in
developing therapeutic devices for infectious disease, announced today
that its Chairman and CEO, James A. Joyce has been named to the
Biodefense Priorities, Programs, and Funding Panel at the 2006
Homeland and Global Security Summit. The Summit is being held on April
11 at the Washington Convention Center in Washington, D.C. The other
panel members are:

-- Steven Perkins, Vice President, Business Development and
Strategy, Northrop Grumman Corporation.

-- Dr. Charles R. Gallaway, Director, Chemical-Biological Defense
Directorate, Defense Threat Regulatory Agency (DTRA).

-- Major General Bruce E. Davis, Commander, Joint Task Force
Civil Support, US Northern Command.

Additional details on the 2006 Homeland and Global Security Summit
can be accessed at
www.globalsecurity.bz/conferences/current_conferences/hgss/2006/index.
asp.

About Aethlon Medical

Aethlon Medical is developing the first medical device to treat
infectious disease. The device, known as the Hemopurifier(TM), is a
broad-spectrum treatment countermeasure against drug and vaccine
resistant bioweapons, naturally evolving pandemic threats such as H5N1
Avian Flu, and chronic infectious disease targets including
Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV). Aethlon
has also initiated research on a second generation Hemopurifier(TM)
that targets the capture of growth factors inherent in the spread of
Cancer. More information on Aethlon Medical and the Hemopurifier(TM)
technology can be found at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and
involve risks and uncertainties. Such forward-looking statements
involve assumptions, known and unknown risks, uncertainties and other
factors which may cause the actual results, performance or
achievements of Aethlon Medical, Inc to be materially different from
any future results, performance, or achievements expressed or implied
by the forward-looking statements. Such potential risks and
uncertainties include, without limitation, the Company's ability to
raise capital when needed, the Company's ability to complete the
development of its planned products, the ability of the Company to
obtain FDA and other regulatory approvals permitting the sale of its
products, the Company's ability to manufacture its products and
provide its services, the impact of government regulations, patent
protection on the Company's proprietary technology, product liability
exposure, uncertainty of market acceptance, competition, technological
change, and other risk factors. In such instances, actual results
could differ materially as a result of a variety of factors, including
the risks associated with the effect of changing economic conditions
and other risk factors detailed in the Company's Securities and
Exchange Commission filings.
Contacts:

Aethlon Medical, Inc.
Jeff Richardson, 858-459-7800 ext. 302
[e-mail]
or
James A. Joyce, 858-459-7800 ext. 301
[e-mail]